comparemela.com

Latest Breaking News On - John jannarone - Page 8 : comparemela.com

Headwaters Capital Calls Out Fishy Bid for Abcam from Danaher in Letter to Stakeholders – Exclusive

Medical specialist company Abcam plc (Nasdaq: ABCM) agreed to $24 a share deal with Danaher on activist pressure Headwaters Capital Management, LLC points out that Danaher issued lower forecasts than Abcam in deal announcement Headwaters Capital believes that the fair value of ABCM’s shares is between $35-$39 per share Shareholders likely won’t know 2023 results […] The post Headwaters Capital Calls Out Fishy Bid for Abcam from Danaher in Letter to Stakeholders – Exclusive appeared first on Corp

Veteran Investment Banker Edward Kovary, Jr Departs EarlyBirdCapital – Exclusive

By John Jannarone Edward Kovary, Jr., a veteran investment banker and pioneer of the special purpose acquisition company (SPAC) model, has departed EarlyBirdCapital, Inc. after 18 years at the firm. Mr. Kovary, who was Head of Capital Markets for most of his tenure, is expected to announce a new role in the near future. “After […]

Online Learning in China: Join Fireside with CFO of QuantaSing Sep 25 at 11AM ET

Distressed Real Estate: Vinson & Elkins Partner Zach Swartz, Live from NYSE

CorpGov hosted a fireside chat from the floor of the New York Stock Exchange with Zach Swartz, Partner at Vinson & Elkins LLP. Mr. Swartz spoke to CorpGov Editor-in-Chief John Jannarone about the current distressed real estate market in the country, its relationship with debt and the economy, among other topics. Watch the full recording […] The post Distressed Real Estate: Vinson & Elkins Partner Zach Swartz, Live from NYSE appeared first on CorpGov.

Targeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSE

Healthcare Edge hosted a fireside chat from the floor of the New York Stock Exchange with Marc Hedrick, M.D., President and CEO of Plus Therapeutics, Inc. (Nasdaq: PSTV). Dr. Hedrick spoke to Healthcare Edge Editor-in-Chief John Jannarone about its novel targeted radio-therapeutics treatment for central nervous system cancer using the latest technology, its future potential […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.